TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26829441
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of VLDL particle size
Study: 26829441
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of endogenous glucose production
Study: 26830335
Drug: Antibiotics adapted
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics adapted to sputum colonization (cases)
Study: 26830335
Drug: Oseltamivir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir treatment (cases)
Study: 26830335
Drug: Antibiotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatments (cases)
Study: 26830335
Drug: Antibiotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatments (controls)
Study: 26830930
Drug: Literature review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature review of effective PTSD treatments
Study: 26831486
Drug: Fear of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fear of procedure and concern about taking a powerful laxative
Study: 26831652
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI with integrated dose counter (2 inhalations/dose; 90 μg/inhalation) twice daily for up to 50 days
Study: 26831652
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI with integrated dose counter
Study: 26831844
Drug: budesonide/formoterol (160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol (160/4.5 μg, one inhalation twice daily and as needed)
Study: 26832367
Drug: Serum 14-3-3η
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 14-3-3η protein levels ≥0.50 ng/ml
Study: 26832367
Drug: Decreases of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreases of 14-3-3η levels by at least 0.76 ng/ml
Study: 26832367
Drug: Baseline 14-3-3η
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline 14-3-3η ≥0.19 ng/ml
Study: 26832367
Drug: Optimal baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal baseline 14-3-3η levels defined by ROC curves at 0.50 ng/ml
Study: 26832753
Drug: Rifabutin at
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin at 150 mg once daily with non-boosted or ritonavir-boosted PIs
Study: 26832753
Drug: Rifabutin at
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin at 300 mg every 3 days with boosted PI
Study: 26834058
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg orally once per day
Study: 26835148
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant (LAC) presence
Study: 26835225
Drug: Afatinib 50
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 50 mg/day plus letrozole 2.5 mg/day
Study: 26835225
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day plus letrozole 2.5 mg/day
Study: 26835225
Drug: Afatinib 30
Normalized name: afatinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 30 mg/day plus letrozole 2.5 mg/day
Study: 26835906
Drug: Biologicals treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologicals treatment
Study: 26836193
Drug: T3D-959 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3D-959 (0.3 to 3.0 mg/kg/day) for 28 days
Study: 26836193
Drug: Lowest tested
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest tested dose of T3D-959
Study: 26837432
Drug: Patient Directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Directed Activity Program (up to three additional 30-minute bouts of activities daily)
Study: 26837440
Drug: NBS20/eltrapuldencel-T (dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBS20/eltrapuldencel-T (dendritic cell-based vaccine)
Study: 26837440
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy and immunotherapy
Study: 26838019
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg IV on days 3 and 5, 5HT3 receptor antagonist days 1-5, dexamethasone 20 mg days 1 and 2, 4 mg po bid days 6, 7, and 8
Study: 26839391
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of chronic total occlusion lesions
Study: 26839475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hemolysis and 1 or more clinical symptoms (abdominal pain, chest pain, dyspnea)
Study: 26839476
Drug: Conventional cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cereal flakes (CC)
Study: 26841930
Drug: Ledipasvir/sofosbuvir fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks
Study: 26843355
Drug: Patch plasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch plasty
Study: 26844278
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E δ-tocotrienol (VEDT) 200 to 3200 mg daily for 13 days before surgery and one dose on the day of surgery
Study: 26844278
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E δ-tocotrienol (VEDT) 200 to 1600 mg daily for 2 weeks before pancreatic surgery
Study: 26844479
Drug: Desensitization regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitization regimen consisting of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m)
Study: 26845282
Drug: Risperidone (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (administered for 6 weeks)
Study: 26846166
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (IM) approach, non-standardized and personalized, multimodal
Study: 26847408
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of asthma and current ICS therapy
Study: 26848057
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50 mg dose)
Study: 26849853
Drug: R-CHOP or
Normalized name: A.E.R. Witch Hazel Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP or R-CVP followed by (90) Y-IT (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab
Study: 26850111
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) treatment administered by Korean medicine doctors (KMDs)
Study: 26850678
Drug: KW-2450 40
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2450 40 mg/kg
Study: 26850678
Drug: KW-2450 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2450 37.5 mg once daily continuously
Study: 26850678
Drug: KW-2450 50
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2450 50 mg/day
Study: 30446785
Drug: BEZ235 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 400 mg bid
Study: 26851029
Drug: BEZ235 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 300 mg bid
Study: 26852132
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment (specifically epirubicin)
Study: 26852132
Drug: Histone deacetylase
Normalized name: Histone deacetylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histone deacetylase small-molecule inhibitors
Study: 26853249
Drug: Pre-hospital medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital medication (PHM)
Study: 26854432
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies targeting castration-resistant prostate cancer
Study: 26855665
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed guar gum (PHGG) 6 g/day
Study: 26856824
Drug: Dosage adjustments
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage adjustments
Study: 26858336
Drug: NEOD001 (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOD001 (24 mg/kg)
Study: 26859538
Drug: Once-daily tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tiotropium 5 μg
Study: 26859538
Drug: Twice-daily tiotropium
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tiotropium 2.5 μg
Study: 26859761
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG-ATCC 53103 (LGG) treatment for 28 days
Study: 26859761
Drug: Post-treatment (Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (Day 56)
Study: 26861602
Drug: Everolimus added
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus added to trastuzumab and paclitaxel as first-line therapy
Study: 26861740
Drug: Sorafenib (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200mg qd titrated to 400mg BID) with infusional 5-FU (225 mg/m(2)/24h) and radiation (28 fractions at 1.8 Gy)
Study: 28282612
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg daily for 2 years
Study: 26861921
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg nonaqueous glucagon
Study: 26861921
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg nonaqueous glucagon
Study: 26861921
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg nonaqueous glucagon
Study: 26861921
Drug: Post-insulin administration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-insulin administration with 75 μg glucagon
Study: 26861921
Drug: Post-insulin administration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-insulin administration with 150 μg glucagon
Study: 26861921
Drug: Post-insulin administration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-insulin administration with 300 μg glucagon
Study: 26863635
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with histamine dihydrochloride and low-dose interleukin-2
Study: 26864194
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg·kg(-1)
Study: 26865277
Drug: miR-92a inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: miR-92a inhibitors
Study: 26865594
Drug: 4-IM (3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-IM (3-dose IM priming with a single booster at 42 months)
Study: 26865594
Drug: 5-IM (3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-IM (3-dose IM priming with boosters at 18 and 42 months)
Study: 26865594
Drug: 7-IM (3-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-IM (3-dose IM priming with boosters at 12, 18, 30, and 42 months)
Study: 26865594
Drug: 8-SQ (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-SQ (licensed priming series of 6 doses with two annual boosters administered subcutaneously)
Study: 26865594
Drug: 8-IM (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-IM (licensed priming series of 6 doses with two annual boosters administered intramuscularly)
Study: 26866015
Drug: AFFITOPE® AD02
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFFITOPE® AD02 (amyloid-beta-targeting vaccine)
Study: 26868114
Drug: DAIR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAIR treatment
Study: 26868433
Drug: Genetic variation
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic variation at ENPP1 locus (rs858340-G)
Study: 26868433
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity assessment via euglycaemic insulin clamp
Study: 26868955
Drug: NAL-NL2 prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL-NL2 prescription rule
Study: 26869376
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197) administered intramuscularly at 24-35 weeks' gestation.
Study: 26869532
Drug: Dengue IgG-antibodies
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue IgG-antibodies
Study: 26869532
Drug: Chikungunya IgG-antibodies
Normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chikungunya IgG-antibodies
Study: 26869690
Drug: Ribavirin +
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin + Abacavir (300 mg orally every 12 h)
Study: 26869690
Drug: Ribavirin alone
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin alone (weight-based dosing)
Study: 26870152
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of multivitamins/minerals
Study: 26870152
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of multivitamins/minerals
Study: 26870733
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV, and promethazine 25 mg IV
Study: 26870733
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of palonosetron, dexamethasone, and promethazine
Study: 26870801
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b vaccine
Study: 26870801
Drug: Diphtheria vaccine
Normalized name: Diphtheria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria vaccine
Study: 26871197
Drug: Low-dose imatinib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose imatinib plus nilotinib
Study: 26871769
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LncPPARδ and risk factors
Study: 26871943
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of alcohol treatment into TB treatment
Study: 26871943
Drug: Drug addiction
Normalized name: INVESTIGATIONAL DRUGS FOR SUBSTANCE ADDICTION TREATMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug addiction
Study: 26873642
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg orally BID for 7 days with 14 days rest until disease progression
Study: 26873687
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy in women
Study: 26876245
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg·kg(-1)·d(-1))
Study: 26877119
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment guided by the therapist
Study: 26880867
Drug: Neoadjuvant radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant radiation with DC injections (50 Gy of external beam radiation in 25 fractions, 4 intratumoral injections of DCs)
Study: 26880867
Drug: Neoadjuvant radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant radiation with DC injections
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 14 days
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 28 days
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 56 days
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 112 days
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 365 days
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score ≥2
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score of 1
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden ≥0.044 hours/day
Study: 26882334
Drug: Daily snapshot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden <0.044 hours/day
Study: 26882907
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in lymphocyte density after chemotherapy
Study: 26882910
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg administered orally
Study: 26883498
Drug: Clopidogrel (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (plus aspirin)
Study: 26884591
Drug: Entrectinib (pan-Trk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib (pan-Trk inhibitor)
Study: 26885381
Drug: MLE Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLE Group (5 injection sites)
Study: 26885381
Drug: non-MLE Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-MLE Group (4 injection sites)
Study: 26885675
Drug: boceprevir (BOC)-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: boceprevir (BOC)-based triple therapy
Study: 26885686
Drug: Reduced-toxicity conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-toxicity conditioning regimen with busulfan (100 mg/m²/d for 4 days), fludarabine (30 mg/m²/d for 5 days), and anti-thymocyte globulins (2.5 mg/kg/d for 2 days)
Study: 26886785
Drug: Antibiotic stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic stewardship programs
Study: 26888022
Drug: Imatinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib therapy (retreatment) for a median of 16.9 months
Study: 26888022
Drug: Longer duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer duration of imatinib before discontinuation
Study: 26888382
Drug: Incretin based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incretin based drugs
Study: 26888535
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor-α receptor 1 (TNF-α R1)
Study: 26888535
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor-α receptor 1 (TNF-α R1) top quartile (>3.63 ng/L) vs bottom quartile (<2.24 ng/L)
Study: 26888800
Drug: Platelet inhibition
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet inhibition (antiplatelet therapy)
Study: 26890209
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for patients found to be deficient or initiating ART or bisphosphonate therapy
Study: 26891037
Drug: Bryostatin-1 10
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 10 μg/m
Study: 26891037
Drug: Bryostatin-1 20
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 20 μg/m
Study: 26893170
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous melatonin
Study: 26895949
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy for 6 months in the GH Rx group, dosage titrated to achieve normal IGF-1 levels.
Study: 26895949
Drug: Non-GH replacement
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-GH replacement therapy in the non-GH Rx group.
Study: 26897675
Drug: High on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High on-treatment platelet reactivity (HPR) defined as platelet reactivity >208 P2Y12 reaction unit
Study: 31672031
Drug: High on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High on-treatment platelet reactivity (HPR)
Study: 26898568
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg q24h alone
Study: 26898568
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg q24h + CBZ 300 mg q12h
Study: 26898607
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily and erlotinib 150mg daily in 28-day cycles